Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.30 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28235234 | 0.77 | CYP3A4 (0.36) | — | |
| SCHEMBL21719433 | 0.75 | CA2 (0.32) | — | |
| SCHEMBL27298566 | 0.73 | KDM4E (0.44) | HSD17B10KDM4ESMN1; SMN2NOTUMP2RX7 | |
| SCHEMBL8473717 | 0.72 | HSD17B10 (0.38) | HSD17B10KDM4ESMN1; SMN2TAAR1 | |
| SCHEMBL20393126 | 0.70 | SMN1; SMN2 (0.37) | HSD17B10KDM4ESMN1; SMN2TAAR1DAO | |
| SCHEMBL9519987 | 0.65 | KIF11 (0.38) | HSD17B10KDM4ESMN1; SMN2TAAR1DAO | |
| SCHEMBL8975943 | 0.65 | HCAR1 (0.41) | HSD17B10KDM4ESMN1; SMN2DAO | |
| SCHEMBL3243395 | 0.65 | HSD17B10 (0.38) | HSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL15777925 | 0.65 | HSD17B10 (0.42) | HSD17B10KDM4ESMN1; SMN2DAO | |
| SCHEMBL27330462 | 0.65 | HSD17B10 (0.33) | HSD17B10KDM4ESMN1; SMN2NOTUMTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460789-B1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9079830-B2 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2460789-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | AKR7A2, AOC2, CBR1 | HSD17B10 211/4885KDM4E 4167/4885SMN1; SMN2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.